Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study tes...
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
About this item
Full title
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Journal of hematology and oncology, 2024-10, Vol.17 (1), p.98-1, Article 98
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Alternative Titles
Full title
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_30fc2ad241184e1492ee95abd9b79005
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_30fc2ad241184e1492ee95abd9b79005
Other Identifiers
ISSN
1756-8722
E-ISSN
1756-8722
DOI
10.1186/s13045-024-01620-y
